Request Demo
Last update 29 Mar 2025
Lu-177-DGUL
Last update 29 Mar 2025
Overview
Basic Info
Drug Type Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals |
Synonyms 177Lu-DOTA-GUL, Lu-177 labelled PSMA-D, PSMA-D GUL |
Target |
Action modulators |
Mechanism PSMA modulators(Prostate-specific membrane antigen modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
1
Clinical Trials associated with Lu-177-DGULNCT05547061
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
100 Clinical Results associated with Lu-177-DGUL
Login to view more data
100 Translational Medicine associated with Lu-177-DGUL
Login to view more data
100 Patents (Medical) associated with Lu-177-DGUL
Login to view more data
1
Literatures (Medical) associated with Lu-177-DGUL01 Jun 2021Nuklearmedizin. Nuclear medicineQ4 · MEDICINE
PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor
Q4 · MEDICINE
Article
Author: Zippel, Claus ; Rahbar, Kambiz ; Albers, Peter ; Krause, Bernd J. ; Maurer, Tobias ; Eiber, Matthias ; Kratochwil, Clemens ; Bohnet-Joschko, Sabine ; Giesel, Frederik L.
100 Deals associated with Lu-177-DGUL
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic castration-resistant prostate cancer | Phase 2 | South Korea | 12 Apr 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Metastatic castration-resistant prostate cancer PSMA-positive PET scan | 28 | 177Lu-DGUL 5.55 GBq | nayzodxgig(ytskoijtgq) = no severe adverse drug reactions were observed yzpvmcdxer (zvdgjeinxh ) View more | Positive | 28 Aug 2023 | |
177Lu-DGUL 7.40 GBq | |||||||
Not Applicable | 224 | Lu-177 PSMA radioligand therapy | wfrsnjlshm(zklhvmfiea) = complete remission with undetectable PSA soywjocjdh (vvpsbgleph ) | Positive | 01 Jul 2018 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free